Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.
Also called NCT02467920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 349 participants
- Registry
-
NCT02467920
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02467920. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2017-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- glargine + exenatide
- Intervention (Drug)
- aspart 30
- Lead sponsor
- Huazhong University of Science and Technology
Record details
- Record id
cardio:ct-nct02467920- Content hash
4fff259036b6ff561c0812821ab7f6eabf908efd4a43b12e121b4b73af2fed52